Minimizing Toxicity from Amivantamab & Lazertinib
Date: Wednesday, February 24
Time: 2 p.m. EST
EGFR-mutated lung cancer therapy can move quickly from “great plan” to “how are we managing these side effects?” In this webinar, Jorge J. Nieva, MD from Keck School of Medicine of USC & USC/Norris Cancer Center will break down amivantamab + lazertinib—the clinical rationale, what the data shows, and what to expect with EGFR/MET-related toxicities—so your team can keep patients supported and on treatment. We’ll also highlight key takeaways from the COCOON Protocol and practical steps to protect quality of life.
We’ll cover:
- Mechanism of action and data supporting amivantamab + lazertinib in EGFRm lung cancer
- Anticipated Adverse Events from EGFR and MET inhibition
- COCOON Protocol findings—what matters in practice
- Practical actions to support quality of life throughout therapy
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Techs Talk: Reducing Delays in Outpatient Oncology Pharmacy
February 11, 2026 | 3:00 PM
Upcoming Webinar
CE Opportunity: Nurses Talk Expanding Eligibility + Improving Outcomes in Allogeneic HCT
February 13, 2026 | 3:00 PM
Upcoming Webinar
Educational & Equity Implications of Biomarker Testing & Targeted Therapy Access in NSCLC
February 17, 2026 | 2:00 PM